PSP Singapore is the national patient advocacy organization for Progressive Supranuclear Palsy (PSP) in Singapore and the broader Southeast Asian region. Founded to address the unique challenges faced by PSP patients and their families in Singapore, the organization serves as the primary resource for disease information, patient support, research collaboration, and healthcare advocacy throughout the city-state and beyond.
Progressive Supranuclear Palsy is a rare neurodegenerative disorder classified as a 4R-tauopathy, characterized by the accumulation of abnormal four-repeat tau protein in the brain [1]. The disease affects approximately 5-10 per 100,000 individuals globally, though prevalence varies by region and population [2].
In Asian populations, PSP has been documented with somewhat different prevalence patterns compared to Western populations [3]. While still considered rare, the disease is increasingly recognized in Singapore and neighboring Southeast Asian countries due to improved diagnostic capabilities and neurological expertise.
The clinical presentation of PSP encompasses multiple phenotypes [4]. Richardson's syndrome (PSP-RS) represents the classic presentation with early postural instability, vertical supranuclear gaze palsy, and progressive parkinsonism. PSP-parkinsonism (PSP-P) accounts for a significant proportion of cases, presenting with more prominent levodopa-responsive parkinsonian features. PSP-progressive gait freezing represents another important phenotype characterized by early gait freezing and freezing of gait.
PSP Singapore was established to provide comprehensive support for the PSP community in Singapore. As a registered charitable organization, the society operates with a governance structure that includes medical advisors, patient representatives, family members, and healthcare professionals. This multi-stakeholder approach ensures that organizational activities address the full spectrum of needs within the PSP community.
The organization maintains active partnerships with international PSP organizations, including CurePSP in the United States and the PSP Europe Network [5], while also developing connections within the Asian region to address the specific needs of Southeast Asian patients.
The mission of PSP Singapore encompasses several core objectives:
Patient and Family Support: Providing comprehensive support services to PSP patients and their families throughout the disease journey. This includes accurate disease information, connection to specialized healthcare services, and emotional support through support groups and counseling services.
Research Promotion and Collaboration: Supporting and facilitating PSP research in Singapore and the broader Southeast Asian region. The organization works with local universities, hospitals, and research institutions to advance understanding of PSP pathophysiology, epidemiology, and potential treatments.
Healthcare Professional Education: Raising awareness of PSP among healthcare professionals in Singapore to improve diagnostic accuracy and patient management. Educational initiatives target neurologists, geriatricians, general practitioners, and allied health professionals.
Public Awareness: Increasing understanding of PSP among the general public to promote early symptom recognition and reduce diagnostic delays.
PSP Singapore maintains research collaborations with leading Singaporean institutions specializing in neurodegenerative diseases:
National Neuroscience Institute (NNI): As Singapore's premier center for neurological disorders, the NNI conducts research into PSP pathophysiology, biomarkers, and clinical management. The institute serves as the primary clinical research partner for PSP-related studies in Singapore.
National University of Singapore (NUS): The university's Yong Loo Lin School of Medicine and the Centre for Molecular Medicine research into tau protein aggregation mechanisms, genetic factors, and potential therapeutic targets.
Singapore General Hospital (SGH): The largest public hospital in Singapore, SGH provides clinical care for PSP patients and participates in clinical trials for novel therapeutics.
Duke-NUS Medical School: This academic medical center conducts translational research on neurodegenerative diseases and provides training for the next generation of neuroscientists and neurologists.
The organization facilitates patient participation in clinical trials, working with pharmaceutical companies and research institutions to ensure Singaporean patients have access to emerging treatments. This includes supporting recruitment for Phase I-III clinical trials investigating tau-targeting therapies, neuroprotective agents, and symptomatic treatments.
Singapore has developed a comprehensive clinical care network for PSP patients:
National Neuroscience Institute (NNI): The NNI Movement Disorders Department provides expert diagnosis and management of PSP and other atypical parkinsonian syndromes. The department offers specialized clinics for movement disorders with neurologists trained in the latest diagnostic criteria and treatment approaches.
Singapore General Hospital Neurology: The neurology department at SGH provides comprehensive care for PSP patients, including movement disorder specialists, neuro-rehabilitation services, and speech therapy.
Tan Tock Seng Hospital: This acute care hospital provides emergency and inpatient services for PSP patients, with neurology consultants experienced in managing complications of PSP.
Khoo Teck Puat Hospital: Located in northern Singapore, this hospital provides accessible neurological care for patients in that region.
Mount Elizabeth Hospitals: Private hospital group with neurology services for patients seeking private care options.
PSP Singapore provides various support services to patients and families:
Information and Education: Comprehensive educational materials about PSP, including disease progression, symptom management, treatment options, and practical advice for daily living. Information is available in English, Mandarin, Malay, and Tamil to serve Singapore's multi-ethnic population.
Support Groups: Regular support group meetings allow patients and caregivers to connect with others facing similar challenges. These groups provide emotional support, practical advice, and shared experiences.
Helpline Services: A dedicated helpline provides immediate support and connects callers with relevant resources.
Caregiver Support: Recognizing the significant burden on caregivers [6], the organization provides resources including respite care information, caregiver training, and connections to home care services.
Financial Assistance: The organization provides financial support programs for patients facing economic hardship, including assistance with medication costs and medical equipment.
PSP Singapore plays a key role in developing PSP awareness and care in Southeast Asia:
ASEAN Neurological Association: Collaboration with regional neurological societies to promote PSP education and research across Southeast Asia.
Asia-Pacific Movement Disorders Society: Participation in regional initiatives to advance movement disorder care in the Asia-Pacific region.
International Research Networks: Contributing to global research efforts on PSP through participation in international registries and clinical trials.
Understanding PSP neuropathology is essential for developing effective treatments [7]:
Tau Protein Accumulation: PSP is classified as a 4R-tauopathy, characterized by predominant deposition of four-repeat tau isoforms in neurofibrillary tangles and glial inclusions.
Subcortical Predominance: Unlike Alzheimer's disease, PSP pathology predominates in subcortical structures including the basal ganglia, brainstem, and cerebellar dentate nucleus.
Cellular Distribution: Tau pathology affects neurons, astrocytes, and oligodendrocytes, contributing to the diverse clinical phenotypes observed in different PSP subtypes [1:1].
Accurate diagnosis of PSP requires distinguishing it from other conditions [8]:
Parkinson's Disease: While both PSP and Parkinson's disease present with parkinsonism, PSP typically shows earlier postural instability, vertical supranuclear gaze palsy, and less levodopa responsiveness [9].
Multiple System Atrophy: Autonomic dysfunction and cerebellar signs help distinguish MSA from PSP.
Corticobasal Degeneration: Asymmetric apraxia and cortical sensory loss typically point toward CBD rather than PSP.
Parkinson Plus Syndromes: Other Parkinson plus syndromes must be considered in the differential diagnosis.
Neuroimaging findings, particularly midbrain atrophy on MRI, support the clinical diagnosis of PSP [10].
The clinical features of PSP include [11]:
Motor Symptoms: Progressive postural instability leading to falls, bradykinesia, axial rigidity, and dystonia.
Ocular Motor Deficits: Vertical supranuclear gaze palsy, particularly affecting downward gaze, is a characteristic finding.
Speech and Swallowing: Dysarthria and dysphagia are common, increasing aspiration risk.
Cognitive Changes: Executive dysfunction, slowed thought processing, and personality changes [12].
Current research priorities include:
Biomarker Development: Identification of reliable biomarkers for early diagnosis and disease progression monitoring [13], including fluid biomarkers, neuroimaging markers, and clinical outcome measures.
Tau-Targeting Therapies: Development of therapies targeting the underlying tau pathology, including aggregation inhibitors, immunotherapy approaches, and gene therapy strategies [14].
Symptomatic Management: Optimization of treatments for motor and non-motor symptoms, including balance disturbances, ocular dysfunction, speech and swallowing difficulties, and cognitive impairment.
Neuroprotective Strategies: Investigation of compounds that may slow or halt disease progression.
PSP significantly impacts quality of life for both patients and caregivers [15]. Key challenges include:
Motor Disability: Progressive gait disturbance and balance impairment lead to frequent falls and loss of independence.
Visual Disturbances: Vertical gaze palsy affects reading, driving, and daily activities requiring downward gaze.
Communication Difficulties: Dysarthria and cognitive impairment compromise verbal communication.
Swallowing Problems: Dysphagia increases risk of aspiration and may require feeding tube placement.
Cognitive Decline: Executive dysfunction and personality changes affect decision-making and social interactions.
PSP Singapore continues to expand its activities in response to emerging research and evolving patient needs. Key priorities include:
Regional Leadership: Establishing Singapore as a regional hub for PSP research and care in Southeast Asia.
Research Infrastructure: Supporting the development of Singapore PSP patient registries and biobanks.
Support Service Expansion: Enhancing geographic coverage and language accessibility of support services.
International Collaboration: Increasing participation in international research consortia and clinical trials.